P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease

Overview

Journal Arterioscler Thromb Vasc Biol

Date 2020 Oct 1

PMID 32998520

Citations 44

Authors

Brandon G Shokoples

Pierre Paradis

Ernesto L Schiffrin

Affiliations

Soon will be listed here.

Abstract

Chronic low-grade inflammation contributes to the development of several diseases, including cardiovascular disease. Adequate strategies to target inflammation in cardiovascular disease are in their infancy and remain an avenue of great interest. The purinergic receptor P2X7 is a ubiquitously expressed receptor that predominately mediates inflammation and cellular death. P2X7 is a ligand-gated cation channel that is activated in response to high concentrations of extracellular ATP, triggering the assembly and activation of the NLRP3 (nuclear oligomerization domain like receptor family pyrin domain containing 3) inflammasome and subsequent release of proinflammatory cytokines IL (interleukin)-1β and IL-18. Increased P2X7 activation and IL-1β and IL-18 concentrations have been implicated in the development of many cardiovascular conditions including hypertension, atherosclerosis, ischemia/reperfusion injury, and heart failure. P2X7 receptor KO (knockout) mice exhibit a significant attenuation of the inflammatory response, which corresponds with reduced disease severity. P2X7 antagonism blunts blood pressure elevation in hypertension and progression of atherosclerosis in animal models. IL-1β and IL-18 inhibition has shown efficacy in clinical trials reducing major adverse cardiac events, including myocardial infarction, and heart failure. With several P2X7 antagonists available with proven safety margins, P2X7 antagonism could represent an untapped potential for therapeutic intervention in cardiovascular disorders.

Citing Articles

Molecular and metabolic landscape of adenosine triphosphate-induced cell death in cardiovascular disease.

Wang W, Wang X, Zhang H, Zhao R, Wang Y, Zhang H World J Cardiol. 2024; 16(12):689-706.

PMID: 39734818 PMC: 11669974. DOI: 10.4330/wjc.v16.i12.689.

Cytosolic delivery of innate immune agonists.

Bharadwaj R, Jaiswal S, Silverman N Trends Immunol. 2024; 45(12):1001-1014.

PMID: 39567309 PMC: 11624987. DOI: 10.1016/j.it.2024.10.007.

P2X receptors exhibit at least three modes of allosteric antagonism.

Oken A, Ditter I, Lisi N, Krishnamurthy I, Godsey M, Mansoor S Sci Adv. 2024; 10(40):eado5084.

PMID: 39365862 PMC: 11451537. DOI: 10.1126/sciadv.ado5084.

Finely ordered intracellular domain harbors an allosteric site to modulate physiopathological function of P2X3 receptors.

Lin Y, Lu Y, Li C, Ma X, Shao M, Gao Y Nat Commun. 2024; 15(1):7652.

PMID: 39227563 PMC: 11372093. DOI: 10.1038/s41467-024-51815-7.

Regulation of transcription factor function by purinergic signalling in cardiovascular diseases.

Tang H, Kong Q, Zhang Z, Wu W, Yuan L, Liu X Purinergic Signal. 2024; .

PMID: 39215950 DOI: 10.1007/s11302-024-10045-8.

References

Gilbert S, Gidley Baird A, Glazer S, Barden J, Glazer A, Teh L . A phase I clinical trial demonstrates that nfP2X -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017; 177(1):117-124. DOI: 10.1111/bjd.15364. View

Bidula S, Dhuna K, Helliwell R, Stokes L . Positive allosteric modulation of P2X7 promotes apoptotic cell death over lytic cell death responses in macrophages. Cell Death Dis. 2019; 10(12):882. PMC: 6877589. DOI: 10.1038/s41419-019-2110-3. View

Giuliani A, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F . Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS One. 2014; 9(9):e107224. PMC: 4165768. DOI: 10.1371/journal.pone.0107224. View

Vonend O, Turner C, Chan C, Loesch A, DellAnna G, S Srai K . Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int. 2004; 66(1):157-66. DOI: 10.1111/j.1523-1755.2004.00717.x. View

Sandanger O, Ranheim T, Vinge L, Bliksoen M, Alfsnes K, Finsen A . The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013; 99(1):164-74. DOI: 10.1093/cvr/cvt091. View

Nicke A, Kuan Y, Masin M, Rettinger J, Marquez-Klaka B, Bender O . A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem. 2009; 284(38):25813-22. PMC: 2757983. DOI: 10.1074/jbc.M109.033134. View

Syed F, Hahn H, Odley A, Guo Y, Vallejo J, Lynch R . Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005; 96(10):1103-9. DOI: 10.1161/01.RES.0000166925.45995.ed. View

Kalogeropoulos A, Georgiopoulou V, Butler J . From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin. 2011; 8(1):113-23. DOI: 10.1016/j.hfc.2011.08.002. View

Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M . Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med. 2016; 8(366):366ra162. DOI: 10.1126/scitranslmed.aaf8463. View

10.

Menzies R, Howarth A, Unwin R, Tam F, Mullins J, Bailey M . Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats. Kidney Int. 2015; 88(5):1079-87. PMC: 4826596. DOI: 10.1038/ki.2015.182. View

11.

Toldo S, Mezzaroma E, Bressi E, Marchetti C, Carbone S, Sonnino C . Interleukin-1β blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014; 64(1):1-6. DOI: 10.1097/FJC.0000000000000106. View

12.

Barth K, Weinhold K, Guenther A, Young M, Schnittler H, Kasper M . Caveolin-1 influences P2X7 receptor expression and localization in mouse lung alveolar epithelial cells. FEBS J. 2007; 274(12):3021-33. DOI: 10.1111/j.1742-4658.2007.05830.x. View

13.

Scheuplein F, Schwarz N, Adriouch S, Krebs C, Bannas P, Rissiek B . NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J Immunol. 2009; 182(5):2898-908. DOI: 10.4049/jimmunol.0801711. View

14.

Cheewatrakoolpong B, Gilchrest H, Anthes J, Greenfeder S . Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun. 2005; 332(1):17-27. DOI: 10.1016/j.bbrc.2005.04.087. View

15.

Adriouch S, Bannas P, Schwarz N, Fliegert R, Guse A, Seman M . ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB J. 2007; 22(3):861-9. DOI: 10.1096/fj.07-9294com. View

16.

Graciano M, Nishiyama A, Jackson K, Seth D, Ortiz R, Prieto-Carrasquero M . Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol. 2007; 294(1):F161-9. PMC: 2567285. DOI: 10.1152/ajprenal.00281.2007. View

17.

Koo T, Lee J, Yan J, Jang J, Ju K, Han M . The P2X7 receptor antagonist, oxidized adenosine triphosphate, ameliorates renal ischemia-reperfusion injury by expansion of regulatory T cells. Kidney Int. 2017; 92(2):415-431. DOI: 10.1016/j.kint.2017.01.031. View

18.

van Wijk B, Gunst Q, Moorman A, van den Hoff M . Cardiac regeneration from activated epicardium. PLoS One. 2012; 7(9):e44692. PMC: 3447884. DOI: 10.1371/journal.pone.0044692. View

19.

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View

20.

Szekely Y, Arbel Y . A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?. Cardiol Ther. 2018; 7(1):25-44. PMC: 5986669. DOI: 10.1007/s40119-018-0104-3. View